Scarica l'app Stockscreener
0.4888
1.02%
0.00495
Precedente Chiudi:
$0.4838
Aprire:
$0.495
Volume 24 ore:
5,961
Relative Volume:
0.14
Capitalizzazione di mercato:
$17.49M
Reddito:
-
Utile/perdita netta:
$-563.30K
Rapporto P/E:
-2.4486
EPS:
-0.1996
Flusso di cassa netto:
$-22.23M
1 W Prestazione:
+0.77%
1M Prestazione:
-6.01%
6M Prestazione:
-48.43%
1 anno Prestazione:
-69.45%
Intervallo 1D:
$0.4802
$0.495
Intervallo di 1 settimana:
$0.4677
$0.4999
Portata 52W:
$0.4677
$2.37
Promis Neurosciences Inc Stock (PMN) Company Profile
Nome
Promis Neurosciences Inc
Settore
Industria
Telefono
416-847-6898
Indirizzo
SUITE 200, 1920 YONGE STREET, TORONTO
Confronta PMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.4888 | 17.49M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc Borsa (PMN) Ultime notizie
Neurvati Neurosciences and GRIN Therapeutics Appoints Gail Farfel, PhD to Their Boards - citybiz
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | PMN Stock News - GuruFocus
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire
Reviewing ProMIS Neurosciences (NASDAQ:PMN) and Earth Science Tech (OTCMKTS:ETST) - Defense World
Promis Neurosciences approves new incentive plan By Investing.com - Investing.com South Africa
Promis Neurosciences approves new incentive plan - Investing.com
PMNProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights - mx.advfn.com
ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying - MSN
ProMIS Neurosciences Reports Q1 2025 Progress and Financials - TipRanks
ProMIS Neurosciences (NASDAQ:PMN) Now Covered by Maxim Group - Defense World
ProMIS Neurosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga
ProMIS Neurosciences (PMN): Maxim Group Initiates Coverage with Buy Rating | PMN Stock News - GuruFocus
Maxim Group Initiates Coverage of ProMIS Neurosciences (PMN) with Buy Recommendation - Nasdaq
ProMIS Neurosciences Announces First Quarter 2025 Financial Resu - GuruFocus
ProMIS Neurosciences (PMN) Advances Alzheimer's Clinical Program - GuruFocus
ProMIS Neurosciences Inc. SEC 10-Q Report - TradingView
ProMIS Neurosciences Announces First Quarter 2025 Financial Results - GlobeNewswire
Planning For Perseverance - Life Science Leader
Multiple System Atrophy Treatment Algorithm, Clinical Trials - openPR.com
Parkinson’s vaccine selectively targets pathogenic αSyn - BioWorld MedTech
ProMIS Neurosciences stock hits 52-week low at $0.62 By Investing.com - Investing.com South Africa
ProMIS Neurosciences stock hits 52-week low at $0.62 - Investing.com India
Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN
ProMIS Neurosciences’ (PMN) Buy Rating Reaffirmed at Guggenheim - Defense World
ProMIS Neurosciences Reports 2024 Financial Turnaround - TipRanks
ProMIS Neurosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PROMIS NEUROSCIENCES Earnings Results: $PMN Reports Quarterly Earnings - Nasdaq
ProMIS Neurosciences Inc. (PMN) reports earnings - Quartz
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights - The Manila Times
Form 424B5 ProMIS Neurosciences - StreetInsider
ProMIS Neurosciences Inc. SEC 10-K Report - TradingView
ProMIS Neurosciences Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
ProMIS to present neurodegenerative disease research By Investing.com - Investing.com Australia
New Diagnostics And Treatments Transform Neurodegenerative Disease Care - Evrim Ağacı
ProMIS to present neurodegenerative disease research - Investing.com India
ProMIS Neurosciences Showcases Preclinical Data on - GlobeNewswire
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference - Yahoo Finance
ProMIS Neurosciences (PMN) Expected to Announce Quarterly Earnings on Monday - Defense World
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart
Multiple System Atrophy Market to Reach New Heights in Growth - openPR
ProMIS to present vaccine data at neurology meeting By Investing.com - Investing.com Australia
ProMIS to present vaccine data at neurology meeting - Investing.com India
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting - The Manila Times
ProMIS Neurosciences to Present Preclinical Data on Computational Vaccine Development for Neurodegenerative Diseases at AAN Annual Meeting - Nasdaq
ProMIS Neurosciences Showcases Preclinical Data on Platform - GlobeNewswire
PROMIS NEUROSCIENCES Earnings Preview: Recent $PMN Insider Trading, Hedge Fund Activity, and More - Nasdaq
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - GlobeNewswire
Promis Neurosciences Inc Azioni (PMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Promis Neurosciences Inc Azioni (PMN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shafmaster Madge K. | Director |
Sep 24 '24 |
Buy |
1.30 |
70,000 |
91,028 |
208,333 |
| Shafmaster Madge K. | Director |
Sep 23 '24 |
Buy |
1.28 |
70,000 |
89,656 |
138,333 |
| Shafmaster Madge K. | Director |
Sep 20 '24 |
Buy |
1.25 |
60,000 |
75,066 |
68,333 |
| GORDON MICHAEL S | 10% Owner |
Sep 16 '24 |
Buy |
1.22 |
76,931 |
94,071 |
76,931 |
| GORDON MICHAEL S | 10% Owner |
Sep 17 '24 |
Buy |
1.40 |
16,292 |
22,809 |
93,223 |
| Kirwin Patrick D. | Director |
Aug 14 '24 |
Buy |
1.25 |
10,000 |
12,492 |
62,983 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):